Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kestra Medical Technologies (KMTS) Amortization of Deferred Charges (2024 - 2026)

Kestra Medical Technologies (KMTS) reported Amortization of Deferred Charges of $469000.0 for Q1 2026, up 98.73% year-over-year from $236000.0 in Q1 2025, and little changed on a QoQ basis from $468000.0 in Q4 2025.

Kestra Medical Technologies (KMTS) has 3 years of Amortization of Deferred Charges data on file, last reported at $469000.0 in Q1 2026.

  • Quarterly Amortization of Deferred Charges rose 98.73% year-over-year to $469000.0 in Q1 2026, while the trailing twelve-month figure through Jan 2026 was $1.8 million (up 51.58% YoY) and the FY2025 annual result came in at $1.4 million, up 129.51% from the prior year.
  • Amortization of Deferred Charges steadied at $469000.0 in Q1 2026 per KMTS's latest filing, from $468000.0 in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $501000.0 in Q2 2024 and bottomed at $82000.0 in Q1 2024.
  • The 3-year median for Amortization of Deferred Charges is $369000.0 (2025), against an average of $336444.4.
  • Peak annual rise in Amortization of Deferred Charges reached 187.8% in 2025, while the deepest fall reached 26.35% in 2025.
  • Tracing KMTS's Amortization of Deferred Charges over 3 years: stood at $234000.0 in 2024, then surged by 100.0% to $468000.0 in 2025, then gained by 0.21% to $469000.0 in 2026.
  • Per Business Quant, the three latest KMTS Amortization of Deferred Charges figures stand at $469000.0 (Q1 2026), $468000.0 (Q4 2025), and $469000.0 (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Intuitive Surgical 156.17 Bn 151.78 Bn 1.83 Bn
2 Becton Dickinson 41.51 Bn 40.49 Bn 2.15 Bn
3 Resmed 30.43 Bn 28.77 Bn 890.98 Mn
4 West Pharmaceutical Services 22.78 Bn 22.26 Bn 296.40 Mn
5 Solventum 13.39 Bn 13.39 Bn 1.10 Bn
6 Cooper Companies 12.33 Bn 12.20 Bn 695.20 Mn
7 Align Technology 11.65 Bn 10.59 Bn 736.59 Mn
8 Baxter International 9.81 Bn 7.77 Bn 891.00 Mn
9 Aptargroup 7.39 Bn 7.19 Bn 351.91 Mn
10 Kestra Medical Technologies 1.13 Bn 840.05 Mn 12.91 Mn

Historic Data

Download Data 🔒
DateValue
Jan 31, 2026 469,000.00
Jan 31, 2026 469,000.00
Oct 31, 2025 468,000.00
Oct 31, 2025 468,000.00
Jul 31, 2025 469,000.00
Jul 31, 2025 469,000.00
Apr 30, 2025 369,000.00
Apr 30, 2025 369,000.00
Jan 31, 2025 236,000.00
Jan 31, 2025 236,000.00
Oct 31, 2024 234,000.00
Oct 31, 2024 234,000.00
Jul 31, 2024 200,000.00
Jul 31, 2024 200,000.00
Apr 30, 2024 501,000.00
Apr 30, 2024 501,000.00
Jan 31, 2024 82,000.00
Jan 31, 2024 82,000.00